Prenylamine (BioDeep_00000182600)

   

human metabolite blood metabolite


代谢物信息卡片


(3,3-diphenylpropyl)(1-phenylpropan-2-yl)amine

化学式: C24H27N (329.21433820000004)
中文名称: 普尼拉明
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(CC1=CC=CC=C1)NCCC(C1=CC=CC=C1)C1=CC=CC=C1
InChI: InChI=1S/C24H27N/c1-20(19-21-11-5-2-6-12-21)25-18-17-24(22-13-7-3-8-14-22)23-15-9-4-10-16-23/h2-16,20,24-25H,17-19H2,1H3

描述信息

C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators

同义名列表

8 个代谢物同义名

(3,3-diphenylpropyl)(1-phenylpropan-2-yl)amine; Prenylamine lactic acid; Prenylamine lactate; b-436Prenylamine; prenylamine; Segontin; Corontin; Difril



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Liang Guo, Luke Coyle, Rory M C Abrams, Raymond Kemper, Eric T Chiao, Kyle L Kolaja. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicological sciences : an official journal of the Society of Toxicology. 2013 Dec; 136(2):581-94. doi: 10.1093/toxsci/kft205. [PMID: 24052561]
  • S Beuck, G Sigmund, A Koch, W Schänzer, A Pokrywka, D Kwiatkowska, M Thevis. Identification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometry. Drug testing and analysis. 2012 Sep; 4(9):701-16. doi: 10.1002/dta.1388. [PMID: 22786790]
  • Antje Lohmann, Mark Aurel Schöttler, Claire Bréhélin, Felix Kessler, Ralph Bock, Edgar B Cahoon, Peter Dörmann. Deficiency in phylloquinone (vitamin K1) methylation affects prenyl quinone distribution, photosystem I abundance, and anthocyanin accumulation in the Arabidopsis AtmenG mutant. The Journal of biological chemistry. 2006 Dec; 281(52):40461-72. doi: 10.1074/jbc.m609412200. [PMID: 17082184]
  • Alexander N Katchman, John Koerner, Toshimasa Tosaka, Raymond L Woosley, Steven N Ebert. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. The Journal of pharmacology and experimental therapeutics. 2006 Mar; 316(3):1098-106. doi: 10.1124/jpet.105.093393. [PMID: 16278312]
  • Thomas Kraemer, Susanne K Roditis, Frank T Peters, Hans H Maurer. Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS. Journal of analytical toxicology. 2003 Mar; 27(2):68-73. doi: 10.1093/jat/27.2.68. [PMID: 12669999]
  • L D Popper, S Batra. Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells. Cell calcium. 1993 Mar; 14(3):209-18. doi: 10.1016/0143-4160(93)90068-h. [PMID: 8500137]
  • E K Schmidt, G E von Unruh, W D Paar, H J Dengler. A gas chromatographic/mass spectrometric assay for prenylamine suitable for pharmacokinetic studies of the racemate and the enantiomers. Biological mass spectrometry. 1992 Feb; 21(2):103-8. doi: 10.1002/bms.1200210208. [PMID: 1606181]
  • W D Paar, D Brockmeier, M Hirzebruch, E K Schmidt, G E von Unruh, H J Dengler. Pharmacokinetics of prenylamine racemate and enantiomers in man. Arzneimittel-Forschung. 1990 Jun; 40(6):657-61. doi: NULL. [PMID: 2397000]
  • Y Gietl, H Spahn, H Knauf, E Mutschler. Single- and multiple-dose pharmacokinetics of R-(-)-and S-(+)-prenylamine in man. European journal of clinical pharmacology. 1990; 38(6):587-93. doi: 10.1007/bf00278587. [PMID: 2373134]
  • W Chao, H Liu, M DeBuysere, D J Hanahan, M S Olson. Identification of receptors for platelet-activating factor in rat Kupffer cells. The Journal of biological chemistry. 1989 Aug; 264(23):13591-8. doi: . [PMID: 2547767]
  • Y Gietl, H Spahn, E Mutschler. Enantioselective disposition of R-(-)- and S-(+)-prenylamine in the rat. Arzneimittel-Forschung. 1989 Aug; 39(8):853-6. doi: NULL. [PMID: 2818674]
  • Y Gietl, H Spahn, E Mutschler. Simultaneous determination of R- and S-prenylamine in plasma and urine by reversed-phase high-performance liquid chromatography. Journal of chromatography. 1988 Apr; 426(2):304-14. doi: NULL. [PMID: 3392143]
  • J G Elferink, M Deierkauf. Felodipine-induced inhibition of polymorphonuclear leukocyte functions. Biochemical pharmacology. 1988 Feb; 37(3):503-9. doi: 10.1016/0006-2952(88)90221-3. [PMID: 3337748]
  • J Milei, A Boveris, S Llesuy, H A Molina, R Storino, D Ortega, S E Milei. Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. American heart journal. 1986 Jan; 111(1):95-102. doi: 10.1016/0002-8703(86)90559-4. [PMID: 3946165]
  • J Milei, A Boveris, H Molina, S Llesuy, R Storino, S E Milei. Prenylamine inhibition of adriamycin-induced myocardiopathy. Acta cardiologica. 1985; 40(4):383-96. doi: ". [PMID: 3876672]
  • G Remberg, M Eichelbaum, G Spiteller, H J Dengler. Metabolism of DL-[14C]prenylamine in man. Biomedical mass spectrometry. 1977 Oct; 4(5):297-304. doi: 10.1002/bms.1200040505. [PMID: 912031]
  • A Yamamoto, S Adachi, Y Matsuzawa, T Kitani, A Hiraoka, K Seki. Studies on drug-induced lipidosis: VII. Effects of bis-beta-diethyl-aminoethylether of hexestrol, chloroquine, homochlorocyclizine, prenylamine, and diazacholesterol on the lipid composition of rat liver and kidney. Lipids. 1976 Aug; 11(8):616-22. doi: 10.1007/bf02532875. [PMID: 9556]
  • W Förster, H U Block. [The effect of oxyfedrin and prenylamine on the biosynthesis of prostaglandin E2 and F2alpha in the rabbit kidney medulla homogenate]. Acta biologica et medica Germanica. 1976; 35(1):121-2. doi: NULL. [PMID: 983597]
  • A W Frolkis, O Fedotowa, T Gilenko, J Rosenbaum. [The influence of various drugs on the intestinal tract]. Deutsche Zeitschrift fur Verdauungs- und Stoffwechselkrankheiten. 1975; 35(5):219-27. doi: NULL. [PMID: 1225511]
  • M Eichelbaum, H J Hengstmann, H J Dengler. [A specific and sensitive method for the analysis of prenylamine and its derivatives in biological materials]. Arzneimittel-Forschung. 1973 Jan; 23(1):74-7. doi: NULL. [PMID: 4740699]
  • R Mornex, R Fitoussi, E Bernier, G Fournier. [Thyroid function and catecholamines]. Actualites endocrinologiques. 1973; 13(0):175-82. doi: NULL. [PMID: 4802083]
  • R Slechtová, B Chundela. Isolation and identification of amphetamine--the metabolic product of Aponeuron, Captagon and Prenylamin. Activitas nervosa superior. 1972; 14(2):119-20. doi: NULL. [PMID: 5040156]
  • M Volz. [Biotransformation of prenylamine in rats]. Arzneimittel-Forschung. 1971 Sep; 21(9):1320-9. doi: NULL. [PMID: 5171786]
  • I Hornke, P Hajdú. [Studies on the metabolism of prenylamine in rats]. Arzneimittel-Forschung. 1970 Jun; 20(6):791-4. doi: NULL. [PMID: 5468896]
  • E Weber, B Schmidt, E Morgenstern, H Mondt. [Fractionation of platelet homogenates. 3. Properties of serotonin-containing vesicles]. Biochemical pharmacology. 1970 Jun; 19(6):1929-42. doi: 10.1016/0006-2952(70)90289-3. [PMID: 5513969]
  • S Silvestri. [Quantitative gas chromatographic determination of prenylamine in proprietary drugs, tissue and urine]. Il Farmaco; edizione pratica. 1969 Jul; 24(7):436-42. doi: NULL. [PMID: 5811728]
  • A F De Schaepdryver, J Tasson, H Lamont. Influence of prenylamine on the excretion of catecholamines and metabolites in man during exercise. European journal of pharmacology. 1969 Mar; 5(4):379-83. doi: 10.1016/0014-2999(69)90116-2. [PMID: 5786362]
  • D Palm, H Fengler, H Grobecker. Urinary excretion of amphetamine in man after administration of prenylamine. Life sciences. 1969 Mar; 8(5):247-57. doi: 10.1016/0024-3205(69)90274-4. [PMID: 5781313]
  • A De Schaepdryver, P Preziosi, U Scapagnini. Brain monoamines and adrenocortical activation. British journal of pharmacology. 1969 Mar; 35(3):460-7. doi: 10.1111/j.1476-5381.1969.tb08287.x. [PMID: 4309262]
  • J A Pedrote, F Vaquero, F Gayoso. [Study of urinary excretion of vanilomandelic acid before and after heart catheterization. Action of prenylamine]. Revista clinica espanola. 1969 Feb; 112(3):291-6. doi: NULL. [PMID: 5345183]
  • M Sandler, M B Youdim. The effect of tyramine, reserpine and other drugs on catecholamine metabolism in man. British journal of pharmacology. 1968 Sep; 34(1):224P-225P. doi: NULL. [PMID: 5676026]
  • K V Flattery, A Shum, G E Johnson. The influence of orally administered prenylamine on the storage and excreti catecholamines in humans and rats. Archives internationales de pharmacodynamie et de therapie. 1968 Sep; 175(1):54-62. doi: NULL. [PMID: 5726461]
  • F Gastaldi, E Molinari. [Prenylamine and urinary elimination of catecholamines]. La Clinica terapeutica. 1968 Jul; 46(1):45-54. doi: NULL. [PMID: 5703790]
  • F Fabris, I Mathis. [Effect of prenylamine on catecholamine and serotonin metabolism in the normal and coronaropathic subject]. Minerva cardioangiologica. 1968 May; 16(5):483-9. doi: NULL. [PMID: 5740765]
  • E Schmid, K Bachmann, J Krautheim, H P Heynen. Studies on the mode of action of prenylamine (Segontin) and other coronary dilating drugs in man. Indian heart journal. 1968 Apr; 20(2):133-40. doi: NULL. [PMID: 5738423]
  • G Deltour. [Hydroxybenzylbenzofuran derivatives of pharmacological and therapeutic interest]. Actualites pharmacologiques. 1968; 21(?):117-55. doi: NULL. [PMID: 4888761]
  • D Palm, H Grobecker, H Fengler. [Metabolism of prenylamine (Segontin)]. Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie. 1968; 260(2):185-6. doi: NULL. [PMID: 4239216]
  • H Balzer, M Makinose. The inhibition of the sarcoplasmic calcium pump produced by agents which react with its lipid component: reserpine, prenylamine, chlorpromazine, imipramine. Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie. 1968; 259(2):151-2. doi: 10.1007/bf00537745. [PMID: 4232647]
  • H J Dengler, M Eichelbaum. [Studies on the behavior of C14-D,L-prenylamine in the organism]. Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie. 1968; 260(2):105-6. doi: NULL. [PMID: 4239146]
  • H Balzer, M Makinose, W Fiehn, W Hasselbach. The binding of the calcium transport inhibitors reserpine, chlorpromazine and prenylamine to the lipids of the membranes of the sarcoplasmic reticulum. Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie. 1968; 260(5):456-73. doi: 10.1007/bf00537360. [PMID: 4236763]
  • R Mornex, L Peyrin, A Gibaud. [Induced adrenalinuria test in thyroid diseases (apropos of 140 tests in 116 subjects)]. La Revue francaise d'endocrinologie clinique, nutrition, et metabolisme. 1967 Mar; 8(2):113-23. doi: NULL. [PMID: 6050710]
  • A Pekkarinen, U K Rinne. Excretion of noradrenaline, adrenaline and vanilmandelic acid in patients with cerebro-vascular disorders during prenylamine treatment. Acta pharmacologica et toxicologica. 1967; 25(3):307-12. doi: 10.1111/j.1600-0773.1967.tb01437.x. [PMID: 5630486]
  • S Greif. [Studies on the effect of phenylpropyldiphenylpropylamine on the metabolism of catecholamines]. Wiener medizinische Wochenschrift (1946). 1966 Nov; 116(45):954-7. doi: NULL. [PMID: 5992464]
  • E Schmid, K Bachman. [Inhibition of the sympathico-adrenal reaction in heart catheterization with prenylamine]. Arzneimittel-Forschung. 1966 Mar; 16(3):448-9. doi: NULL. [PMID: 6013858]
  • H Klensch. [Circulatory reactivity and plasma noradrenaline in man during smoking before and after prenylamine treatment]. Zeitschrift fur Kreislaufforschung. 1965 Aug; 54(8):771-6. doi: NULL. [PMID: 5864998]
  • H BRAUNSTEINER, S SAILER, F SANDHOFER. [THE EFFECT OF PHENYLPROPYLDIPHENYLAMINE ON THE CONCENTRATION OF FREE FATTY ACIDS IN HUMAN PLASMA]. Klinische Wochenschrift. 1965 Apr; 43(?):355-7. doi: 10.1007/bf01484653. [PMID: 14291090]
  • F GAWELLEK, H ECKERT. [CATECHOLAMINE EXCRETION AND THE CLINICAL PICTURE IN THE MANAGEMENT OF CARDIAC INFARCTION AND CORONARY INSUFFICIENCY WITH N 3-PHENYLPROPYL -(2) 1, 1-DIPHENYL-PROPYL-(3)-AMINE]. Das Deutsche Gesundheitswesen. 1964 Jul; 19(?):1339-46. doi: NULL. [PMID: 14243103]
  • H M RAUEN, I AEBERT. [THE EXCRETION OF 3-METHOXY-4-HYDROXYMANDELIC ACID IN MAN AFTER SEGONTIN ADMINISTRATION]. Klinische Wochenschrift. 1964 May; 42(?):443-5. doi: 10.1007/bf01486023. [PMID: 14230119]
  • G GABOR. THERAPEUTIC ACTION OF A NEW ANTI-ANGINOUS DRUG. Therapia Hungarica (English edition). 1964; 12(?):9-14. doi: NULL. [PMID: 14133137]
  • E TRILLA SANCHEZ, J M BELLONCANEIRO, M TORNER SOLER. [CLINICAL TRIALS WITH PHENYL-DIPHENYL-PROPYL-AMINE IN CORONARY INSUFFICIENCY]. Revista espanola de cardiologia. 1963 Oct; 16(?):873-84. doi: ". [PMID: 14117507]
  • F WOHLRAB. [The effect of segontin on histochemically demonstrable monoamino oxidase activity in the guinea pig kidney]. Klinische Wochenschrift. 1961 Jul; 39(?):699. doi: 10.1007/bf01477797. [PMID: 13786201]
  • A VOELKEL. [Clinical studies on monoamine metabolism under the influence of segontin]. La Medicina del lavoro. 1960 Aug; 55(?):1433-4. doi: NULL. [PMID: 15445566]